STOCK TITAN

Clearside Biomedical, Inc. - CLSD STOCK NEWS

Welcome to our dedicated page for Clearside Biomedical news (Ticker: CLSD), a resource for investors and traders seeking the latest updates and insights on Clearside Biomedical stock.

Clearside Biomedical, Inc. (symbol: CLSD) is a prominent clinical biopharmaceutical company based in Alpharetta, Georgia. Specializing in the development of pharmacological therapies, the company's primary focus is on treating blinding diseases of the eye through their innovative suprachoroidal space (SCS) technology.

Clearside Biomedical's cornerstone is their SCS Microinjector®, a proprietary device that facilitates a non-surgical, office-based procedure. This technology allows for targeted delivery of therapies directly to the macula, retina, or choroid, which could potentially preserve and enhance vision for patients suffering from severe eye conditions.

One of the company's significant achievements is the robust safety profile and encouraging efficacy data from multiple studies using the SCS Microinjector®. These findings have been featured in numerous oral and poster presentations, highlighting the potential of Clearside’s technology in ophthalmic therapeutics.

Clearside Biomedical continues to advance its pipeline of ophthalmic therapies, collaborating with various partners to bring innovative treatments to market. The company remains committed to improving the quality of life for individuals with vision-threatening diseases through groundbreaking research and development.

Recent Achievements:

  • Clinical data utilizing Clearside’s suprachoroidal delivery technology featured in multiple presentations.
  • Enhanced safety and efficacy data presented, showcasing the utility of the SCS Microinjector®.

Investors and media can reach out to Jenny Kobin and Remy Bernarda for more information at ir@clearsidebio.com or by calling (678) 430-8206.

Rhea-AI Summary
Clearside Biomedical, Inc. announced that multiple oral and poster presentations featuring clinical data utilizing their Suprachoroidal Delivery Technology will be delivered at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting. The presentations will cover various studies on different therapies for eye diseases such as nAMD, uveitic macular edema, diabetic retinopathy, and choroidal melanoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.85%
Tags
none
-
Rhea-AI Summary
Clearside Biomedical, Inc. has successfully completed recruitment for its ODYSSEY Phase 2b clinical trial. The trial is evaluating the safety and efficacy of CLS-AX, a tyrosine kinase inhibitor for neovascular age-related macular degeneration. Topline data is expected in Q3 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.24%
Tags
-
Rhea-AI Summary
Clearside Biomedical, Inc. (Nasdaq: CLSD) will report its third quarter 2023 financial results on November 13, 2023. A webcast and conference call will be held at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Participants can access the webcast on the Clearside website and join the call by dialing the provided numbers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.22%
Tags
conferences earnings
Rhea-AI Summary
Clearside Biomedical announces completion of enrollment in Phase 3 clinical trial for ARCATUS in China, positive progress for suprachoroidal delivery platform
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
-
Rhea-AI Summary
Clearside Biomedical CFO to participate in panel discussion at JonesTrading Healthcare Summit.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
conferences
-
Rhea-AI Summary
Clearside Biomedical CEO to participate in panel discussion at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
conferences
Rhea-AI Summary
Clearside Biomedical, Inc. (Nasdaq: CLSD) Reports Progress on Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD, Announces Financial Results, and Provides Corporate Update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.6%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
conferences
-
Rhea-AI Summary
Clearside Biomedical, Inc. will report its second quarter 2023 financial results on August 14, 2023. A webcast and conference call will be held to discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
conferences earnings
Rhea-AI Summary
Clearside Biomedical, Inc. (Nasdaq: CLSD) Presents Favorable Safety and Efficacy Data for CLS-AX at ASRS 41st Annual Scientific Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.1%
Tags
none

FAQ

What is the current stock price of Clearside Biomedical (CLSD)?

The current stock price of Clearside Biomedical (CLSD) is $1.08 as of November 22, 2024.

What is the market cap of Clearside Biomedical (CLSD)?

The market cap of Clearside Biomedical (CLSD) is approximately 80.4M.

What does Clearside Biomedical, Inc. specialize in?

Clearside Biomedical specializes in developing pharmacological therapies for blinding eye diseases using their proprietary SCS Microinjector® technology.

Where is Clearside Biomedical, Inc. located?

Clearside Biomedical, Inc. is located at 1220 Old Alpharetta Rd., Suite 300, Alpharetta, GA, United States.

What is the SCS Microinjector®?

The SCS Microinjector® is Clearside Biomedical's proprietary device designed for non-surgical, targeted delivery of therapies to the macula, retina, or choroid.

How does Clearside Biomedical's technology benefit patients?

Their technology allows for targeted drug delivery to specific parts of the eye, which may help preserve and improve vision in patients with severe eye diseases.

What recent achievements has Clearside Biomedical reported?

Clearside Biomedical has reported a robust safety profile and encouraging efficacy data from studies using the SCS Microinjector®.

Who can be contacted for investor and media inquiries?

For investor and media inquiries, Jenny Kobin and Remy Bernarda can be contacted at ir@clearsidebio.com or (678) 430-8206.

What kind of presentations feature Clearside's technology?

Clearside's suprachoroidal delivery technology has been featured in multiple oral and poster presentations.

What diseases is Clearside Biomedical targeting with their therapies?

Clearside Biomedical is targeting sight-threatening eye diseases with their pharmacological therapies.

Is Clearside Biomedical's procedure surgical?

No, Clearside Biomedical's SCS Microinjector® enables a non-surgical, office-based procedure.

What is the significance of Clearside's technology in ophthalmology?

Clearside's technology offers a potential breakthrough in delivering effective treatments for serious eye conditions, potentially preserving and improving vision.

Clearside Biomedical, Inc.

Nasdaq:CLSD

CLSD Rankings

CLSD Stock Data

80.39M
70.22M
7.39%
23.17%
2.35%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
ALPHARETTA